Kalaris Therapeutics Inc [NASDAQ: KLRS] gained 14.25% on the last trading session, reaching $4.57 price per share at the time.
Kalaris Therapeutics Inc represents 18.70 million in outstanding shares, while the company has a total market value of $76.49 million with the latest information. KLRS stock price has been found in the range of $4.05 to $7.26.
If compared to the average trading volume of 59.43K shares, KLRS reached a trading volume of 10831776 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Kalaris Therapeutics Inc [KLRS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KLRS shares is $16.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KLRS stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Kalaris Therapeutics Inc shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on September 03, 2025. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Neutral. The new note on the price target was released on July 23, 2025, representing the official price target for Kalaris Therapeutics Inc stock. Previously, the target price had yet another raise to $20, while Leerink Partners analysts kept a Outperform rating on KLRS stock.
The Price to Book ratio for the last quarter was 1.61, with the Price to Cash per share for the same quarter was set at 5.28.
Trading performance analysis for KLRS stock
Kalaris Therapeutics Inc [KLRS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 78.52. With this latest performance, KLRS shares gained by 77.13% in over the last four-week period, additionally sinking by -53.32% over the last 6 months – not to mention a drop of -52.69% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KLRS stock in for the last two-week period is set at 83.03, with the RSI for the last a single of trading hit 0.67, and the three-weeks RSI is set at 0.45 for Kalaris Therapeutics Inc [KLRS]. The present Moving Average for the last 50 days of trading for this stock 2.70, while it was recorded at 3.86 for the last single week of trading, and 6.86 for the last 200 days.
Kalaris Therapeutics Inc (KLRS) Capital Structure & Debt Analysis
According to recent financial data for Kalaris Therapeutics Inc. ( KLRS), the Return on Equity (ROE) stands at -50.68%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -39.26%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Kalaris Therapeutics Inc’s Return on Invested Capital (ROIC) is -82.73%, showcasing its effectiveness in deploying capital for earnings.
Kalaris Therapeutics Inc (KLRS) Efficiency & Liquidity Metrics
Based on Kalaris Therapeutics Inc’s (KLRS) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Kalaris Therapeutics Inc (KLRS) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Kalaris Therapeutics Inc. (KLRS) effectively leverages its workforce, generating an average of -$7323333.33 per employee. The company’s liquidity position is robust, with a Current Ratio of 11.98% and a Quick Ratio of 11.98%, indicating strong ability to cover short-term liabilities.
Kalaris Therapeutics Inc [KLRS]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Kalaris Therapeutics Inc posted -0.61/share EPS, while the average EPS was predicted by analysts to be reported at -0.52/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.09. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KLRS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Kalaris Therapeutics Inc go to 55.30%.
An analysis of Institutional ownership at Kalaris Therapeutics Inc [KLRS]
There are presently around $69.92%, or 83.42%% of KLRS stock, in the hands of institutional investors.
